Material Agreement (Form 8-K)

Item 1.01 Entry into a Material Definitive Agreement.

On December 30, 2025, Gasherbrum Bio, Inc. ("Gasherbrum"), a wholly-owned subsidiary of Structure Therapeutics Inc. (the "Company"), entered into an agreement (the "GNE Agreement") with Genentech, Inc. ("Genentech") and F. Hoffmann-La Roche Ltd ("Roche" and together with Genentech, "GNE") that was the culmination of discussions initiated by Genentech's inquiry regarding the availability of a license to certain patents of Gasherbrum that cover a class of oral GLP-1 receptor agonists that is different from aleniglipron. Under the GNE Agreement, Gasherbrum, on behalf of itself and its affiliates, granted to GNE and its affiliates a non-exclusive, sublicensable, royalty-bearing license, under certain patents owned or controlled by Gasherbrum or its affiliates ("Licensed Patents"), to make, use, sell, offer for sale and import products that contain CT-996, a proprietary compound owned by GNE, as an active ingredient ("GNE Products") and a covenant not to assert certain potential future patents with respect to GNE's and its affiliates' manufacture, use, sale, offer for sale or importation of GNE Products.

Genentech will pay Gasherbrum a one-time, non-refundable payment of $100 million within thirty (30) days after execution of the GNE Agreement. Genentech agreed to pay Gasherbrum royalties at a low single digit rate on net sales of GNE Products on a country-by-country basis until the expiration of the last valid claim of a Licensed Patent, or, if sooner, a specified date.

The non-exclusive license granted under the GNE Agreement does not encumber any of the Company's ongoing programs, including aleniglipron and other GLP-1 receptor agonists, dual amylin and calcitonin receptor agonists such as ACCG-2671 and ACCG-3535, and modulators of GIPR and GCGR. GNE and its affiliates do not have any patent prosecution or enforcement rights with respect to the Licensed Patents.

Either party may terminate the GNE Agreement for the other party's uncured material breach, and Gasherbrum may terminate the GNE Agreement if GNE or any of its affiliates or sublicensees commences a patent challenge of any Licensed Patent, subject to customary exceptions.

The foregoing description of the GNE Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the GNE Agreement, a copy of which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2025.